These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26278893)

  • 21. Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib.
    Haddad FG; Nasnas C; Sasaki K; Paul S; Issa GC; Rausch C; Jabbour E; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2024 Jul; 24(7):484-487. PubMed ID: 38503634
    [No Abstract]   [Full Text] [Related]  

  • 22. Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia.
    Inoue H; Taji H; Yamada K; Iriyama C; Saito T; Kato H; Yanada M; Yamamoto K; Matsukawa N
    Intern Med; 2020 Oct; 59(19):2419-2421. PubMed ID: 32611965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography.
    Wang HC; Lee CS; Liu TC
    Kaohsiung J Med Sci; 2015 Mar; 31(3):165-6. PubMed ID: 25744241
    [No Abstract]   [Full Text] [Related]  

  • 24. Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.
    Yun S; Anwer F; Vincelette ND
    BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24810451
    [No Abstract]   [Full Text] [Related]  

  • 25. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
    Rousselot P; Mollica L; Guilhot J; Guerci A; Nicolini FE; Etienne G; Legros L; Charbonnier A; Coiteux V; Dartigeas C; Escoffre-Barbe M; Roy L; Cony-Makhoul P; Dubruille V; Gardembas M; Huguet F; Réa D; Cayssials E; Guilhot F; Bergeron A; Molimard M; Mahon FX; Cayuela JM; Busque L; Bouchet S
    Br J Haematol; 2021 Jul; 194(2):393-402. PubMed ID: 34195988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A Case of Drug-Induced Organizing Pneumonia Caused by Dasatinib].
    Sato M; Watanabe S; Aoki N; Asakawa K; Moriyama H; Oshima Y; Koya T; Okazuka K; Kikuchi T
    Gan To Kagaku Ryoho; 2018 May; 45(5):851-854. PubMed ID: 30026450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversible pre-capillary pulmonary hypertension due to dasatinib.
    Buchelli Ramirez HL; Álvarez Álvarez CM; Rodríguez Reguero JJ; García Clemente MM; Casan Clarà P
    Respir Care; 2014 May; 59(5):e77-80. PubMed ID: 24149673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dasatinib in chronic myelogenous leukemia.
    Kathula SK
    N Engl J Med; 2006 Sep; 355(10):1062; author reply 1063-4. PubMed ID: 16957155
    [No Abstract]   [Full Text] [Related]  

  • 29. Dasatinib-induced pulmonary arterial hypertension - A rare late complication.
    Ibrahim U; Saqib A; Dhar V; Odaimi M
    J Oncol Pharm Pract; 2019 Apr; 25(3):727-730. PubMed ID: 29343154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dasatinib-related left ventricular dysfunction in a patient with chronic myelogenous leukemia.
    Kawanami Y; Yamaguchi K; Yamasaki S; Kagawa Y; Sato H; Watanabe N; Endo A; Yoshitomi H; Tanabe K
    J Echocardiogr; 2024 Jun; 22(2):99-101. PubMed ID: 37314625
    [No Abstract]   [Full Text] [Related]  

  • 31. Dasatinib-Induced Pulmonary Arterial Hypertension.
    Zeb H; El-Kersh K
    Am J Ther; 2020 Aug; 28(6):e695-e696. PubMed ID: 32769395
    [No Abstract]   [Full Text] [Related]  

  • 32. Double-edged sword of the new cancer therapeutics.
    Force T
    Circulation; 2012 May; 125(17):2057-8. PubMed ID: 22451582
    [No Abstract]   [Full Text] [Related]  

  • 33. [Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma].
    Ryczek R; Góra-Tybor J; Betkier-Lipińska K; Cwetsch A
    Pol Merkur Lekarski; 2013 Jun; 34(204):342-4. PubMed ID: 23882932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
    Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
    Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.
    Aoyama R; Ishikawa J; Harada K
    J Cardiol; 2020 Feb; 75(2):203-207. PubMed ID: 31416783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
    Dumitrescu D; Seck C; ten Freyhaus H; Gerhardt F; Erdmann E; Rosenkranz S
    Eur Respir J; 2011 Jul; 38(1):218-20. PubMed ID: 21719499
    [No Abstract]   [Full Text] [Related]  

  • 37. Change of right ventricular systolic pressure can indicate dasatinib-induced pulmonary arterial hypertension in chronic myeloid leukemia.
    Lee SE; Hyun Kong J; Kim SH; Jang EJ; Chung NG; Cho B; Joong Oh S; Jung HE; Youn HJ; Chung WB; Kim DW
    Cancer Med; 2021 Mar; 10(5):1515-1524. PubMed ID: 33590711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dasatinib-Induced Pulmonary Arterial Hypertension.
    Orlikow E; Weatherald J; Hirani N
    Can J Cardiol; 2019 Nov; 35(11):1604.e1-1604.e3. PubMed ID: 31590985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Repeated partially reversible pulmonary arterial hypertension related to dasatinib: a case report and literature review].
    Jin J; Xu XM; Wang C
    Zhonghua Jie He He Hu Xi Za Zhi; 2016 Feb; 39(2):83-7. PubMed ID: 26879609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New drugs: paliperidone, dasatinib, and decitabine.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(2):298-302. PubMed ID: 17510013
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.